Acetylcholinesterase (AChE) has been regarded as an attractive target in the treatment of Alzheimer’s disease (AD) (Amat-ur-Rasool et al., 2021), the most common neurodegenerative disease in old age that is characterized clinically by progressive memory loss, cognitive dysfunction, language disorders, and personality changes (Dong et al., 2012; Kepp, 2012). The gene discussed is ACHE; the disease is Alzheimer disease.